BRAIN and NERVE－神経研究の進歩67巻11号

2015年11月発行

記事購入ページに移動

増大特集 ギラン・バレー症候群のすべて—100年の軌跡

ギラン・バレー症候群の予後，予後関連因子

著者： 海田賢一¹

所属機関： ¹防衛医科大学校内科学講座神経・抗加齢血管内科

ページ範囲：P.1411 - P.1419

ギラン・バレー症候群（GBS）の長期予後は免疫療法が確立された現在でも満足できるものではない。予後不良例を早期に同定し，より強力な治療を施すことがGBSの予後改善につながる。GBSの予後関連因子は臨床的，電気生理学的，生物学的因子に分類され，臨床的因子が予後予測に最も有用である。より正確な予後予測システムの開発のために前方視的臨床研究が本邦を含め国際的に行われている。

参考文献

1) Raphael JC, Masson C, Morice V, Brunel D, Gajdos P, et al: The Landry-Guillain-Barré syndrome. Study of prognostic factors in 223 cases ［Article in French］. Rev Neurol (Paris) 142: 613-624, 1986

2) Winer JB, Hughes RA, Osmond C: A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 51: 605-612, 1988

3) Ropper AH, Wijdicks EFM, Truax BT: Guillain-Barré Syndrome. F.A. Davis Company, Philadelphia, 1991, pp267-269

4) Rajabally YA, Uncini A: Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 83: 711-718, 2012

5) Forsberg A, Press R, Holmqvist LW: Residual disability 10 years after falling ill in Guillain-Barré syndrome: a prospective follow-up study. J Neurol Sci 317: 74-79, 2012

6) Roodbol J, de Wit MC, Aarsen FK, Catsman-Berrevoets CE, Jacobs BC: Long-term outcome of Guillain-Barré syndrome in children. J Peripher Nerv Syst 19: 121-126, 2014

7) McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, et al: Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23: 347-353, 1988

8) Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meché FG: Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 53: 598-604, 1999

9) Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, et al: Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 56: 758-765, 2001

10) van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, et al: A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 6: 589-594, 2007

11) Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, et al: Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 76: 968-975, 2011

12) Hughes RA, Cornblath DR: Guillain-Barré syndrome. Lancet 366: 1653-1666, 2005

13) van Doorn PA, Ruts L, Jacobs BC: Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 7: 939-950, 2008

14) Yuki N, Hartung HP: Guillain-Barré syndrome. N Engl J Med 366: 2294-2304, 2012

15) Durand MC, Porcher R, Orlikowski D, Aboab J, Devaux C, et al: Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol 5: 1021-1028, 2006

16) Walgaard C, Lingsma HF, Ruts L, Drenthen J, van Koningsveld R, et al: Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 67: 781-787, 2010

17) Chiò A, Cocito D, Leone M, Giordana MT, Mora G, et al: Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 60: 1146-1150, 2003

18) Kaida K, Kusunoki S, Kanzaki M, Kamakura K, Motoyoshi K, et al: Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain-Barré syndrome. Neurology 62: 821-824, 2004

19) 三井良之, 有村公良, 梶　龍兒, 神田　隆, 桑原　聡, 他: GBS疫学調査: 本邦における脱髄型, 軸索型の頻度および臨床的特徴〜prospectivestudyの結果から〜（班員　楠　進). 厚生労働科学研究費補助金難治性疾患克服研究事業. 免疫性神経疾患に関する調査研究. 平成23年度総括・分担研究報告書. 2012年3月, pp151-153

20) Sharshar T, Chevret S, Bourdain F, Raphaël JC; French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med 31: 278-283, 2003

21) Kaida K, Kusunoki S, Kanzaki M, Kamakura K, Motoyoshi K, et al: Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain-Barré syndrome. Neurology 62: 821-824, 2004

22) Arami MA, Yazdchi M, Khandaghi R: Epidemiology and characteristics of Guillain-Barré syndrome in the northwest of Iran. Ann Saudi Med 26: 22-27, 2006

23) Funakoshi K, Kuwabara S, Odaka M, Hirata K, Yuki N: Clinical predictors of mechanical ventilation in Fisher/Guillain-Barré overlap syndrome. J Neurol Neurosurg Psychiatry 80: 60-64, 2009

24) Cornblath DR, Mellits ED, Griffin JW, McKhann GM, Albers JW, et al: Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol 23: 354-359, 1988

25) Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, et al: Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 44: 780-788, 1998

26) Koga M, Yuki N, Hirata K, Morimatsu M, Mori M, et al: Anti-GM1 antibody IgG subclass: a clinical recovery predictor in Guillain-Barré syndrome. Neurology 60: 1514-1518, 2003

27) Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, et al: Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 182: 212-218, 2007

28) Strauss J, Aboab J, Rottmann M, Porcher R, Polito A, et al: Plasma cortisol levels in Guillain-Barré syndrome. Crit Care Med 37: 2436-2440, 2009

29) Saifudheen K, Jose J, Gafoor VA, Musthafa M: Guillain-Barre syndrome and SIADH. Neurology 76: 701-704, 2011

30) Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, et al: Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 66: 597-603, 2009

31) Ruts L, Drenthen J, Jacobs BC, van Doorn PA; Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 74: 1680-1686, 2010

32) 海田賢一: Guillain-Barré症候群の予後因子. 臨床神経53: 1315-1318, 2013

-Iの使用成績調査結果報告. 診療と新薬50: 1103-1128, 2013

34) Kaida K, Kusunoki S: Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. J Neuroimmunol 223: 5-12, 2010